High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Recruiting

Phase 2

Radiation & Pembrolizumab & ChemotherapyHigh Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Sponsor:

Emory University

Code:

NCT06492759

Conditions

Anatomic Stage IV Breast Cancer AJCC v8

Metastatic Triple-Negative Breast Carcinoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Radiation Therapy

Pembrolizumab

Nab-paclitaxel

Paclitaxel

Carboplatin

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-21. This information was provided to ClinicalTrials.gov by Emory University on 2026-04-17.